Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Recruiting 2Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Mesothelioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Carboplatin 5niraparib 2Taxes 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Bevacizumab 2talazoparib 1sargramostim 1palbociclib 1oregovomab 1olaparib 1epacadostat 1dostarlimab 1birinapant 1atezolizumab 1aldesleukin 1Specimen Handling 1Sirolimus 1Selenium 1Polymerase Chain Reaction 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Metformin 1Magnetic Resonance Spectroscopy 1Letrozole 1Injections 1Hyperthermic Intraperitoneal Chemotherapy 1Gene Expression Profiling 1Fulvestrant 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Fallopian Tube Neoplasms × talazoparib × Clear all
NCT02627430 2016-07-26

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡